Back to Research Home
ITOCiTonic Holdings Ltd.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus
$2.80−13.31%
As of 23 Oct 2026Mkt cap —
Stage 13
AVOID
Fundamentals
3.0/75
Technical
—/15
Independent
—/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- −42.1%
- 3M
- −29.6%
- 6M
- −53.2%
- 1Y
- —
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- —
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- —
- Operating margin
- -171.9%
- FCF margin
- -618.6%
- Current ratio
- 8.8x
Growth
- Revenue growth
- +16.7%Latest FY YoY
- Revenue CAGR
- −8.4%
- EPS CAGR
- —
- FCF CAGR
- —
Capital
- Share-count trend
- +15.6%3Y annualised
- Net cash
- $1M
Annual trend
- CAGR 2022–2025
- −8.4%
- Latest · 2025
- $0B
- YoY
- +16.7%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- insufficient-data
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded